nivolumab,pembrolizumab,atezolizumab
bms,merck,roche
['urothelial carcinoma', 'nivo', 'import', 'urothelial']
dr. discusses the adjuvant immunotherapies in urothelial carcinoma and highlights the ongoing trials. important to point out that adjuvant nivo should only be considered if persistent disease after neoadjuvant gem-cis or cis-ineligible patient. #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer